|
Corporate Social Responsibility
Our vision
Compliance with CSR standards
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Sanofi-aventis addresses issues identified as being important for the pharmaceutical sector through a series of policies, procedures and initiatives that respect cultural and legal environments in the countries where the Group operates.
For human rights, the Group adheres the Universal Declaration of Human Rights (UDHR) principles as well as other individuals rights established by organizations adhering to the United Nations system. The principles set forth in universal human rights documents apply to people and organizations, and consequently, to businesses. For each of the Group’s various stakeholders (employees, patients, healthcare professionals, investors, suppliers, NGOs and local communities), sanofi-aventis has determined the relevant area of human rights. Over several years, the Group developed a set of policies to ensure the respect for human rights. Sanofi-aventis took this commitment one step farther in 2007, when the Group became a member of the EdH initiative. The EdH "Businesses for Human Rights" initiative comprises seven French-based international groups, and was created following exchanges with organizations such as Business Leaders Initiative on Human Rights (BLIHR) and the French section of Amnesty International. The Group adheres to several codes, rules and principles such as: the International Labor Organization (ILO), the United Nations Global Compact, and the directives issued by the Organization for Economic Cooperation and Development (OECD). Moreover, sanofi-aventis respects the international rules specific to the pharmaceutical industry, in particular with regard to: - Clinical trials and animal testing; in particular rules developed by professional associations (European, American and Japanese) concerning clinical trials transparency ILAR (Institute for Laboratory Animal Research) and UFAW (Universities Federations for Animal Welfare) guidelines on animal testing;
- Promotional practices such as Organization for Economic Co-operation and Development (OECD) directives geared to multinational firms and particularly concerning good business practices, anti-corruption and illegal payments;
- medicines and vaccines donations, "ethical criteria" of the World Health Organization (WHO) with regard to drug promotion, as well as codes from the International Federation of Pharmaceutical Manufacturers Associations (I.F.P.M.A) and the European Federation of Pharmaceutical Industries and Associations (E.F.P.I.A) concerning good commercial practices;
- WHO recommendations on drug donations. In addition to these external codes and standards, a set of principles and policies applicable to the entire Group was defined. The most important of these are listed in Internal Policies section.
|
